A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

Inclusion Criteria:

- Have been discontinued from study JAIW, and completed at least 16 weeks on treatment.

Exclusion Criteria:

- Have significant uncontrolled cerebro-cardiovascular (e.g., myocardial infarction
[MI], unstable angina, unstable arterial hypertension, severe heart failure, or
cerebrovascular accident), respiratory, hepatic, renal, gastrointestinal, endocrine,
hematologic, neuropsychiatric disorders, or abnormal laboratory values that developed
during a previous baricitinib study that, in the opinion of the investigator, pose an
unacceptable risk to the participant if investigational product continues to be
administered.

- Have a known hypersensitivity to baricitinib or any component of this investigational
product.

- Had investigational product permanently discontinued at any time during a previous
baricitinib study, except for participants who had investigational product
discontinued during originating study because of rescue with an oral systemic AD
therapy (e.g., corticosteroid, cyclosporine, methotrexate).

- Had temporary investigational product interruption continue at the final study visit
of a previous baricitinib study and, in the opinion of the investigator, this poses an
unacceptable risk for the participant's participation in the study.

- Pregnant or breastfeeding.